CDK4 and breast cancer: Finally, we observed a higher mean of RET relative expression at baseline in the CDK4/6i-resistant compared to the -sensitive samples (1.08 and 0.93, respectively) in the neoadjuvant NeoPalAna trial (Supplementary Figure S3), which assessed the antiproliferative activity of the CDK4/6i palbociclib in breast cancer neoadjuvant setting (40).